Immunogene therapy as a treatment for malignant brain tumors in young mice

Journal of Neurosurgery

Volumn 105 PEDIATRICS, Issue SUPPL. 1, 2006, Pages 65-70

  Glick, Roberta P ^a   Lichtor, Terry ^b   Henry, Lin ^b   Tarlock, Katherine ^b   Cohen, Edward P ^b  

^a Department of Ambulatory and Community Health   (United States)

^b NONE

Author keywords

Brain neoplasm; Gene therapy; Glioma; Immunotherapy; Mouse; Pediatric neurosurgery

Indexed keywords

INTERLEUKIN 2; ANTINEOPLASTIC AGENT; CANCER VACCINE;

ALLOGRAFT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CANCER; CELL BASED GENE THERAPY; CONTROLLED STUDY; FIBROBLAST; GENETIC ENGINEERING; GLIOMA; HUMAN; IMMUNIZATION; IMMUNOCOMPETENT CELL; IMMUNOCYTOTOXICITY; IMMUNOGENETICS; IMMUNOLOGICAL MEMORY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR CELL; ACTIVE IMMUNIZATION; AGE; ANIMAL; BRAIN TUMOR; C57BL MOUSE; GENETIC TRANSDUCTION; IMMUNOLOGY; SECRETION; TRANSPLANTATION;

AGE FACTORS; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CANCER VACCINES; FIBROBLASTS; GLIOMA; IMMUNOTHERAPY, ACTIVE; INTERLEUKIN-2; MICE; MICE, INBRED C57BL; TRANSDUCTION, GENETIC;

EID: 33748454309     PISSN: 00223085     EISSN: 00223085     Source Type: Journal    
DOI: 10.3171/jns.2006.105.1.65     Document Type: Article

References (32)

1. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186:1177-1182, 1997
2. Borden EC, Sondel PM: Lymphokines and cytokines as cancer treatment. Immunotherapy realized. Cancer 65 (3 Suppl):800-814, 1990
3. Bubenik J, Viotenok NN, Kieler J, Prassolov VS, Chumakov PM, Bubenikova D, et al: Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumors in nu/nu mice. Immunol Lett 19:279-282, 1988
4. Colbére-Garapin F, Horodniceanu F, Kourilsky P, Garapin A: A new dominant hybrid selective marker for higher eukaryotic cells. J Mol Biol 150:1-14, 1981
5. Deshmukh P, Glick RP, Lichtor T, Moser R, Cohen EP: Immunogene therapy with interleukin-2-secreting fibroblasts for intracerebrally metastasizing breast cancer in mice. J Neurosurg 94:287-292, 2001
6. Fakhrai H, Shawler DL, Gjerset R, Naviaux RK, Koziol J, Royston I, et al: Cytokine gene therapy with interleukin-2 transduced fibroblasts: effects of IL-2 dose on anti-tumor immunity. Hum Gene Ther 6:591-601, 1995
7. Gabrilove JL, Jakubowski A: Hematopoietic growth factors: biology and clinical application. J Natl Cancer Inst Monogr 10:73-77, 1990
8. Gandolfi L, Solmi L, Pizza GC, Bertoni F, Muratori R, DeVinci C, et al: Intratumoral echo-guided injection of interleukin-2 and cytokine-activated killer cells in hepatocellular carcinoma. Hepatogastroenterology 36:352-356, 1989
9. + T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity. Cancer Res 60:2449-2457, 2000
10. Glick RP, Lichtor T, de Zoeten E, Deshmukh P, Cohen EP: Prolongation of survival of mice with glioma treated with semiallogeneic fibroblasts secreting interleukin-2. Neurosurgery 45:867-874, 1999
11. Griffitt W, Glick RP, Lichtor T, Haughton DE, Cohen EP: Development of a new mouse brain tumor model using implantatable micro-cannulas. J Neurooncol 41:117-120, 1999
12. Heimberger AB, Crotty LE, Archer GE, McLendon RE, Friedman A, Dranoff G, et al: Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 103:16-25, 2000
13. Herrlinger U, Kramm CM, Johnston KM, Louis DN, Finkelstein D, Reznikoff G, et al: Vaccination for experimental gliomas using GM-CSF transduced glioma cells. Cancer Gene Ther 4:345-352, 1997
14. Hui KM, Sim T, Foo TT, Oei AA: Tumor rejection mediated by transfection with allogeneic class I histocompatibility gene. J Immunol 143:3835-3843, 1989
15. Insug O, Ku G, Ertl HCJ, Blaszczyk-Thurin M: A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 22:613-621, 2002
16. Kelso A: Cytokines: structure, function and synthesis. Curr Opin Immunol 2:215-225, 1989
17. Kim TS, Cohen EP: Interleukin-2-secreting mouse fibroblasts transfected with genomic DNA from murine melanoma cells prolong the survival of mice with melanoma. Cancer Res 54:2531-2535, 1994
18. Kim TS, Russell SJ, Collins MK, Cohen EP: Immunity to B16 melanoma in mice immunized with IL-2-secreting allogeneic mouse fibroblasts expressing melanoma-associated antigens. Int J Cancer 51:283-289, 1992
19. Lichtor T, Glick RP, Kim TS, Hand R, Cohen EP: Prolonged survival of mice with glioma injected intracerebrally with double cytokine-secreting cells. J Neurosurg 83:1038-1044, 1995
20. Lichtor T, Glick RP, Tarlock K, Moffett S, Mouw E, Cohen EP: Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors. Cancer Gene Ther 9:464-469, 2002
21. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA: High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA 256:3117-3124, 1986
22. Markowitz D, Goff S, Bank A: Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167:400-406, 1988
23. Natsume A, Mizuno M, Ryuke Y, Yoshida J: Antitumor effect and cellular immunity activation by murine interferon-β gene transfer against intracerebral glioma in mouse. Gene Ther 6:1626-1633, 1999
24. Pizza G, Viza D, DeVince C, Vichi-Pascuuchi JM, Busutti L, Bergami T: Intralymphatic administration of interleukin-2 (IL-2) in cancer patients: a pilot study. Lymphokine Res 7:45-48, 1988
25. Rosenberg SA, Lotze MT, Mulé JJ: NIH Conference. New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med 108:853-864, 1988
26. + cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. Proc Natl Acad Sci U S A 93:10399-10404, 1996
27. Sarna G, Collins J, Figlin R, Robertson P, Altrock B, Abels R: A pilot study of intralymphatic interleukin-2. II. Clinical and biological effects. J Biol Response Mod 9:81-86, 1990
28. Sobol RE, Fakhrai H, Shawler DL, Gjerset R, Dorigo O, Carson C, et al: Interleukin-2 gene therapy in a patient with glioblastoma. Gene Ther 2:164-167, 1995
29. Tahara H, Zeh HJ III, Storkus WJ, Pappo I, Watkins SC, Gubler U, et al: Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 54:182-189, 1994
30. Valmori D, Lévy F, Miconnet I, Zajac P, Spagnoli GC, Rimoldi D, et al: Induction of potent antitumor CTL responses by recombinant vaccinia encoding a melan-A peptide analogue. J Immunol 164:1125-1131, 2000
31. Yamada G, Kitamura Y, Sonoda H, Harada H, Taki S, Mulligan RC, et al: Retroviral expression of the human IL-2 gene in a murine T cell line results in a cell growth autonomy and tumorigenicity. Embo J 6:2705-2709, 1987
32. Yu JS, Burwick JA, Dranoff G, Breakefield XO: Gene therapy for metastatic brain tumors by vaccination with granulocytemacrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther 8:1065-1072, 1997